证券代码：300430 证券简称：诚益通 公告编号：2025-028 北京诚益通控制技术集团股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： （四）会议召开时间： 1、现场会议召开时间：2025 年 5 月 15 日 14:00； 2、网络投票时间：2025年5月15日。其中通过深圳证券交易所交易系统进行 网络投票的具体时间为：2025年5月15日上午9:15-9:25,9:30-11:30，下午 13:00-15:00。通过深圳证券交易所互联网投票系统投票的具体时间为：2025年5 月15日上午9:15至下午15:00期间的任意时间。 （五）现场会议召开地点：北京市大兴区生物医药产业基地庆丰西路 27 号 6 层会议室。 1、本次股东大会没有增加、变更、否决议案的情况； 2、本次股东大会不涉及变更前次股东大会决议。 北京诚益通控制技术集团股份有限公司（以下简称"公司"）2024 年度股 东大会会议通知已于 2025 年 4 月 24 日以公告形式发出。本次会议采取现场投票 和网络投票相结合的方式召开，现 ...

北京市朝阳区东三环中路 5 号财富金融中心 3、11、12 层（100020） 电话：+86 10 6502 8888 传真：+86 10 6502 8866 www.hylandslaw.com 法律意见书 致：北京诚益通控制技术集团股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》《上市公司股东 会规则》《北京诚益通控制技术集团股份有限公司章程》（以下简称"《公司章 程》"）的规定，北京本所律师事务所接受北京诚益通控制技术集团股份有限公 司（以下简称"公司"）委托，指派穆铁虎律师、郑玲玲律师（以下简称"本所 律师"）出席公司 2024 年度股东大会会议，并对本次股东大会会议的相关事项 依法进行见证。 为出具本法律意见书，本所律师审查了公司提供的相关文件资料。现按照律 师行业的业务标准、道德规范和勤勉尽责精神，对公司本次股东大会会议的召集 召开及其他相关事项依法出具并提供如下见证法律意见： 一、本次股东大会的召集、召开程序 经查验，公司本次股东大会是由公司董事会召集召开的。关于召开本次股东 大会的通知，公司已经依规及时在深圳证券交易所网站上予以公告，本次股东大 会拟审议的议案也已充分披露。 ...

Core Viewpoint - The human brain engineering sector experienced a slight increase of 0.47% on May 13, with a total capital outflow of 592.5 million [1] Group 1: Market Performance - The number of stocks that increased in value was 12, while 11 stocks saw a decline [1] - The top-performing stocks in the sector included Chengyitong (up 5.7%), Saily Medical (up 4.66%), and Aipeng Medical (up 3.6%) [1] - The stocks with the largest declines included *ST Shengxun (down 3.69%), ST Huaton (down 3.37%), and Yanshan Technology (down 2.51%) [1] Group 2: Capital Flow - The net capital inflow for the top-performing stock Chengyitong was 3.02 million, representing a net capital ratio of 8.44% [1] - Saily Medical had a net capital inflow of 31.18 million, with a net capital ratio of 9.10% [1] - In contrast, stocks like Lepu Medical and Keda Xunfei experienced net capital outflows of 0.75 million and 0.06 million, respectively [1]

Group 1: Industry Overview - The smart manufacturing sector is experiencing a competitive landscape where international giants dominate the high-end market, while local companies seek differentiation [2][3] - The rehabilitation medical device industry faces short-term adjustment pressures but is transitioning towards quality-based competition due to stricter regulations and market purification mechanisms [3] Group 2: Financial Performance - In 2024, the company achieved a revenue of CNY 958 million, with a net profit attributable to shareholders of CNY 96.54 million [7] - Revenue from the smart manufacturing segment decreased by 21.85% year-on-year, while the rehabilitation medical segment saw a decline of 9.73% [16] Group 3: Strategic Initiatives - The company is focused on a "dual-wheel drive" strategy, enhancing its product matrix in smart manufacturing while expanding into emerging sectors like biomanufacturing and food [5][12] - In the rehabilitation medical field, the company aims to build a high-value product system and penetrate grassroots medical markets [5][12] Group 4: Product Development and Innovation - The company has established a dual-track strategy for brain-computer interface (BCI) development, focusing on both invasive and non-invasive technologies [10][11] - Three prototypes of rehabilitation devices integrating BCI technology were successfully launched in July 2024, with plans for market registration [8][9] Group 5: Market Challenges and Responses - The company faces challenges from reduced capital expenditure willingness among clients and structural demand fatigue, impacting order delivery cycles [16] - To mitigate these challenges, the company is tightening cash flow management and optimizing funding safety margins [16]

Group 1 - The A-share brain-computer interface sector experienced an initial rise, with Aipeng Medical increasing by over 8% [1] - Chengyitong, Rongtai Health, and Xiangyu Medical all saw increases of over 5% [1] - Companies such as Dineike and Sanbo Neuroscience also followed the upward trend [1]

Core Insights - Brain-computer interface (BCI) technology enables direct communication between the brain and external devices, revolutionizing human-machine interaction and integrating advanced technologies such as neuroscience, AI, and new materials [2][4] - The global BCI industry is projected to reach $7.63 billion by 2029, indicating significant growth potential [4] - China and the United States are leading in BCI development, with a notable number of companies and products entering clinical stages [6][7] Industry Overview - The BCI industry is characterized by a competitive landscape with active companies in over 40 countries, primarily in the US and China, where the number of companies exceeds 100 [7] - As of early 2024, China holds 55.62% of the global patent technology in BCI, leading all countries [6] - The industry is still in its early stages, with many startups emerging and a significant increase in patent applications and funding events [55] Key Companies - **Qiangnao Technology**: Founded in 2018, it specializes in non-invasive BCI technology and has over 200 core patents, with a goal to help 1 million disabled individuals regain mobility [10][12] - **Brain Tiger Technology**: Established in 2021, it focuses on flexible invasive BCI technology and has made significant breakthroughs in core technologies [13][15] - **Brain Land Technology**: Founded in 2018, it integrates BCI technology with medical big data and AI, holding 147 patents as of April 2025 [20][21] - **Borecon**: Founded in 2021, it has developed high-performance BCI systems and has over 100 patents [24][25] - **Weiling Medical**: Established in 2019, it is focused on BCI technology and has initiated clinical research for implantable BCI systems [28] - **Roulint Technology**: Founded in 2020, it specializes in non-invasive BCI technology for consumer electronics and medical applications, holding 161 patents [33] - **Aipeng Medical**: Established in 2001, it has invested in BCI technology and developed several non-invasive BCI products [36][37] - **Kedou BCI**: Founded in 2016, it focuses on invasive BCI technology and has developed various microelectrodes and related devices [40][41] - **Sanbo Neuroscience**: Established in 2003, it has over 50 patents and is involved in clinical applications of BCI technology for neurological disorders [43] - **Chengyitong**: Founded in 2011, it has developed several non-invasive BCI prototypes and holds 303 patents, covering key areas of BCI technology [46] Technological Insights - BCI technology is categorized into invasive, semi-invasive, and non-invasive types, with a focus on improving accuracy, feedback speed, and safety [50][52] - The majority of BCI product development is currently centered on non-invasive devices due to their higher safety and market acceptance [53] - As of 2024, there are 222 registered medical devices related to BCI in China, with 194 classified as Class II medical devices [53]

Industry Insights - The CyberSense flexible microelectrode implantation robot, developed by the Brain and Brain-like Intelligence Laboratory of the Chinese Academy of Sciences, has successfully supported various flexible microelectrode implantation studies, enabling precise implantation in animal brains [1] - The brain-computer interface (BCI) industry is experiencing significant advancements in technology, leading to breakthroughs in applications such as motor recovery, language communication, and hearing restoration [1][2] - Recent policy support from the national level, including the National Healthcare Security Administration's decision to separately list prices for new BCI technologies, is paving the way for clinical application and service charge pathways [1] Company Developments - Cheng Yi Tong is a national high-tech enterprise that has expanded into the BCI-driven rehabilitation medical field through mergers and technological innovation, forming a collaborative ecosystem of "industry + medical" [3] - Xiang Yu Medical, also a national high-tech enterprise, focuses on the research, production, and sales of rehabilitation medical devices, aiming to seize opportunities in BCI medical applications amid an aging population and the "silver economy" [3]

北京诚益通控制技术集团股份有限公司 独立董事制度 （2025 年 4 月修订） 第一章 总则 第一条 为进一步完善北京诚益通控制技术集团股份有限公司（以下简称"公司"）的 治理结构, 促进公司的规范运作, 维护公司利益，保障全体股东，特别是中小股东的合 法权益不受侵害，参照中国证监会《上市公司独立董事管理办法》等法规及《公司章程》 的有关规定，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务, 并与公司及其主要股东（主 要股东，是指持有公司5%以上股份，或者持有股份不足5%但对公司有重大影响的股东）、 实际控制人不存在直接或者间接利害关系，或者其他可能妨碍其进行独立客观判断关系 的董事。 第三条 上市公司董事会成员中应当至少包括三分之一独立董事。上市公司董事会下设 薪酬与考核、审计、提名等专门委员会的，独立董事应在审计委员会、提名委员会、薪 酬与考核委员会成员中占多数，并担任召集人。独立董事对公司及全体股东负有诚信和 勤勉义务。独立董事应当按照相关的法律法规和《公司章程》的要求，认真履行职责， 维护公司整体利益，尤其要关注中小股东的合法权益不受损害。 第四条 独立董事原则上最多在 3 家境内上 ...

北京诚益通控制技术集团股份有限公司 市值管理办法 第一章 总则 第一条 为加强上市公司市值管理工作，进一步规范北京诚益通控制技术集 团股份有限公司（ 以下简称（ 公司"）的市值管理行为，维护公司、投资者及其 他利益相关者的合法权益，依据（ 中华人民共和国公司法》 中华人民共和国证 券法》 深圳证券交易所创业板股票上市规则》 深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》 上市公司监管指引第 10 号— —市值管理》及其他有关法律法规和（ 北京诚益通控制技术集团股份有限公司章 程》 以下简称（ （ 公司章程》"）的规定，并结合公司的实际情况制定（ 北京 诚益通控制技术集团股份有限公司市值管理制度》 以下简称 本制度"）。 第二条 本制度所指市值管理，是指公司以提高公司质量为基础，为提升公 司投资价值和股东回报能力和水平而实施的战略管理行为。 第三条 上市公司应牢固树立回报股东意识，采取措施保护投资者尤其是中 小投资者利益，诚实守信、规范运作、专注主业、稳健经营，推动经营水平和发 展质量提升，并在此基础上做好投资者关系管理，提高信息披露质量和透明度， 必要时积极采取措施提振投资者信心， ...

北京诚益通控制技术集团股份有限公司 募集资金管理制度 （2025 年 4 月修订） 第一章 总则 第一条 为规范公司募集资金管理，提高募集资金使用效率，根据《公司法》、 《证券法》等有关法律、法规和规范性文件及《公司章程》的有关规定，制定本 制度。 第二条 本制度所称募集资金是指公司通过向不特定对象或特定对象发行证 券（包括股票、可转换公司债券等）募集并用于特定用途的资金。 第三条 募集资金到位后，公司应及时办理验资手续，由具有证券从业资格 的会计师事务所出具验资报告。 （二）募集资金专户账号、该专户涉及的募集资金项目、存放金额； （三）公司一次或者十二个月内累计从专户中支取的金额超过 5,000 万元 或者募集资金净额的 20%的，公司及商业银行应当及时通知保荐机构或者独立财 务顾问； 第四条 公司应当建立并完善募集资金存储、使用、变更、监督和责任追究 的制度，明确募集资金使用的分级审批权限、决策程序、风险控制措施及信息披 露要求，保证募集资金项目的正常进行。 第五条 募集资金投资项目通过公司的子公司或公司控制的其他企业实施的， 公司应当确保该子公司或受控制的其他企业遵守本募集资金管理制度。 第二章 募集资 ...